Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 14, 2012, Pages 4750-4755

  Curtin, Michael L ^a   Robin Heyman, H ^a   Frey, Robin R ^a   Marcotte, Patrick A ^a   Glaser, Keith B ^a   Jankowski, James R ^a   Magoc, Terrance J ^a   Albert, Daniel H ^a   Olson, Amanda M ^a   Reuter, David R ^a   Bouska, Jennifer J ^a   Montgomery, Debra A ^a   Palma, Joann P ^a   Donawho, Cherrie K ^a   Stewart, Kent D ^a   Tse, Chris ^a   Michaelides, Michael R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Aminopyrazoles; Antitumor activity; Aurora B kinase inhibitors; Diaminopyrimidines; KDR kinase inhibitors

Indexed keywords

ABT 348; ANTINEOPLASTIC AGENT; AURORA B KINASE; CENISERTIB; COLONY STIMULATING FACTOR 1; ENZYME INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FLT3 LIGAND; PYRAZOLE DIAMINOPYRIMIDINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; STEM CELL FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HYDROGEN BOND; MOUSE; NONHUMAN; RACEMIZATION; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TUMOR VOLUME;

AMINATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863451235     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.05.067     Document Type: Article

References (13)

1. T. Marumoto, D. Zhang, and H. Saya Nat. Rev. Cancer 5 2005 42
2. N. Matthews, C. Visintin, B. Hartzoulakis, A. Jarvis, and D.L. Selwood Expert Rev. Anticancer Ther. 6 2006 109
3. H. Yang, T. Burke, J. Dempsey, B. Diaz, E. Collins, J. Toth, R. Beckmann, and X. Ye FEBS Lett. 579 2005 3385
4. F. Girdler, K.E. Gascoigne, P.A. Eyers, S. Hartmuth, C. Crafter, K.M. Foote, N.J. Keen, and S.S. Taylor J. Cell Sci. 119 2006 3664
5. N. Ferrara, H.P. Gerber, and J. LeCouter Nat. Med. 9 2003 669
6. For a review of the most recently approved KDR inhibitor, see: H. Commander, G. Whiteside, and C. Perry Drugs 71 2011 1355
7. T. Fojo Oncologist 13 2008 277
8. Y. Dai, K. Hartandi, Z. Ji, A.A. Ahmed, D.H. Albert, J.L. Bauch, J.J. Bouska, P.F. Bousquet, G.A. Cunha, K.B. Glaser, C.M. Harris, D. Hickman, J. Guo, J. Li, P.A. Marcotte, K.C. Marsh, M.D. Moskey, R.L. Martin, A.M. Olson, D.J. Osterling, L.P. Pease, N.B. Soni, K.D. Stewart, V.S. Stoll, P. Tapang, D.R. Reuter, S.K. Davidsen, and M.R. Michaelides J. Med. Chem. 50 2007 1584
9. M.L. Curtin, H.R. Heyman, R.R. Frey, N.B. Soni, P.A. Marcotte, L.J. Pease, K.B. Glaser, T.J. Magoc, P. Tapang, D.H. Albert, D.J. Osterling, A.M. Olson, J.J. Bouska, Z. Guan, R.L. Martin, L.C. Preusser, J.S. Polakowsi, K.D. Stewart, C. Tse, S.K. Davidsen, and M.R. Michaelides Bioorg. Med. Chem. Lett. 22 2012 3208
10. J. McLaughlin, V. Markovtsov, H. Li, S. Wong, M. Gelman, Y. Zhu, C. Franci, D.W. Lang, E. Pali, J. Lasaga, C. Low, F. Zhao, B. Chang, T.L. Gururaja, W. Xu, M. Baluom, D. Sweeney, D. Carroll, A. Sran, S. Thota, M. Parmer, A. Romane, G. Clemens, E. Grossbard, K. Qu, Y. Jenkins, T. Kinoshita, V. Taylor, S.J. Holland, A. Argade, R. Singh, P. Pine, D.G. Payan, and Y. Hitoshi J. Cancer Res. Clin. Oncol. 136 2010 99
11. Y. Dai, Y. Guo, R.R. Frey, Z. Ji, M.L. Curtin, A.A. Ahmed, D.H. Albert, L. Arnold, T. Barlozzari, J.L. Bauch, J.J. Bouska, P.F. Bousquet, G.A. Cunha, K.B. Glaser, J. Guo, J. Li, P.A. Marcotte, K.C. Marsh, M.D. Moskey, L.J. Pease, K.D. Stewart, V.S. Stoll, P. Tapang, N. Wishart, S.K. Davidsen, and M.R. Michaelides J. Med. Chem. 48 2005 6066
12. W.J. McClellan, Y. Dai, C. Abad-Zapatero, D.H. Albert, J.J. Bouska, K.B. Glaser, T.J. Magoc, P.A. Marcotte, D.J. Osterling, K.D. Stewart, S.K. Davidsen, and M.R. Michaelides Bioorg. Med. Chem. Lett. 21 2011 5620
13. After this work was completed, the FDA approved the first dianilinopyrimidine RTK inhibitor, pazopanib, for the treatment of renal cell carcinoma. For an account of the discovery of this compound, see: P.A. Harris, A. Boloor, M. Cheung, R. Kumar, R.M. Crosby, R.G. Davis-Ward, A.H. Epperly, K.W. Hinkle, R.N. Hunter, J.H. Johnson, V.B. Knick, C.P. Laudeman, D.K. Luttrell, R.A. Mook, R.T. Nolte, S.K. Rudolph, J.R. Szewczyk, A.T. Truesdale, J.M. Veal, L. Wang, and J.A. Stafford J. Med. Chem. 51 2008 4632